ArriVent BioPharma, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Zhengbin Yao (CEO) and Winston Kung (CFO) issued standard Sarbanes-Oxley Section 302 and 906 certifications for the Form 10-Q quarter ended June 30, 2026, filed August 12, 2026. Both officers certified that the report contains no untrue material statements, that financial statements fairly present the company's condition and results, and that disclosure controls and internal controls over financial reporting are effective. No specific transactions, dollar amounts, or operational changes are disclosed in these certification exhibits.
Why this rating
Routine quarterly officer certifications mandated by SOX; no business, financial, or control issues flagged. Boilerplate compliance filing.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.